High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma

International Journal of Colorectal Disease

Volumn 14, Issue 2, 1999, Pages 128-130

  Fahlke, J ^a   Ridwelski, K ^a   Lippert, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Amifastine; Metastatic colorectal carcinoma; Palliative treatment; Reduction of gastrointestinal side effects

Indexed keywords

AMIFOSTINE; FLUOROURACIL; FOLINIC ACID; RADIOPROTECTIVE AGENT;

ANEMIA; ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

AMIFOSTINE; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FLUOROURACIL; LEUCOVORIN; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS;

EID: 0033026941     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840050197     Document Type: Article

References (15)

1. Alberts DS, Speicher LA, Krutzsch M, Wymer J, Capizzi RL, Conlon J, Barrett A, Aickin M (1996) WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cells. Eur J Cancer 32 A [Suppl 4]: 17-20
2. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richmann S, Legaspi A, Waldmann S, Morrell L, et al. (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630
3. Facchini T, Belpomme D, Kemp G, et al. (1995) Amifostine selectively protects against cumulative toxicities of cyclophosphamide and cisplatin. Eur J Cancer 31 A: 107
4. Glover D, Glick JH, Weiler C, et al. (1986) WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 4: 584-588
5. Köhne C, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Schubert U, Hecker H, Dorken B, Schmoll HJ (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418-426
6. List AF, Heaton R, Glinsmann-Gibson B, et al. (1996) Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23: 58-63
7. Nagy B, Dale PJ, Grdina DJ (1986) Protection against cis-diamminedichlorioplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl) amino] ethanethiol. Cancer Res 46: 1132-1135
8. Patchen ML, MacVittie TJ, Souza LM (1992) Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR 2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 22: 773-779
9. Piedbois P, Buyse M, Blijhman G, Glimelius B, Herrmann R, Valone F (1996) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960-969
10. Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schulz JJ, Veach SR, McCulloch W, Baker L, Schein P (1994) Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419
11. Shpall EJ, Stemmer SM, Hami L, et al. (1994) Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132-3137
12. Treskes M, Boven E, van de Loodrecht AA, et al. (1994) Effects of the modulating agent WR 2721 on myelotoxicity and antitumor activity in carboplatin treated mice. Eur J Cancer 30 A: 183-187
13. Valeriote F, Tolen S (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR 2721. Cancer Res 42: 4330-4331
14. Wassermann TH, Phillips TL, Ross G, et al. (1981) Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFU by WR 2721. Cancer Clin Trials 4: 3-6
15. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, et al. (1994) Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 5: 233-237